Learn trading wrote a post · Nov 25, 2024 20:32

CGTX

Cognition Therapeutics (NASDAQ: CGTX)reported new biomarker analysis from their Phase 2 'SHINE' study in mild-to-moderate Alzheimer's disease. The analysis revealed that patients with lower baseline plasma p-tau217 levels treated with CT1812 showed a 95% reduction in cognitive decline compared to placebo, representing a 2.7-point improvement on ADAS-Cog11 over six months. The study demonstrated normalization of key Alzheimer's disease indicators, including reductions in GFAP (neuroinflammatory biomarker), NfL (neurodegenerative biomarker), and impacts on amyloid biology through reductions in Aβ42 and Aβ40 proteins. The company plans to present complete biomarker results at scientific conferences in 2025.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

7076 Views

Comment

Learn trading

Followers

Following

178

Visitors